Insulin glargine (HOE901) - First responsibilities: understanding the data and ensuring safety

被引：11
|
作者：
Buse, J [1 ]
机构：
[1] Univ N Carolina, Diabet Care Ctr, Durham, NC 27713 USA
来源：
DIABETES CARE | 2000年 / 23卷 / 05期
关键词：
D O I：
10.2337/diacare.23.5.576
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：576 / 578
页数：3
相关论文
共 41 条
  • [31] Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis
    Riccardo C. Bonadonna
    Didac Mauricio
    Dirk Müller-Wieland
    Nick Freemantle
    Gregory Bigot
    Celine Mauquoi
    Alice Ciocca
    Mireille Bonnemaire
    Pierre Gourdy
    Diabetes Therapy, 2021, 12 : 1073 - 1097
  • [32] Glycemic Control and Safety Profile of Insulin Glargine 300 U/mL in Older Adults-REALI Pooled Data Analysis
    Bonadonna, Riccardo C.
    Mauricio, Didac
    Muller-Wieland, Dirk
    Freemantle, Nick
    Bigot, Gregory
    Mauquoi, Celine
    Ciocca, Alice
    Bonnemaire, Mireille
    Gourdy, Pierre
    DIABETES, 2019, 68
  • [33] Efficacy and Safety of Insulin Glargine vs. NPH Insulin in Subjects With Type 2 Diabetes Mellitus Uncontrolled on Oral Agents: A Pooled Analysis of RCT Data
    Bolli, Geremia B.
    Porcellati, Francesca
    Lin, Jay
    Wang, Edward
    Lucidi, Paolo
    Fanelli, Carmine G.
    DIABETES, 2012, 61 : A265 - A265
  • [34] Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis
    Gourdy, Pierre
    Bonadonna, Riccardo C.
    Mauricio, Didac
    Mueller-Wieland, Dirk
    Mauquoi, Celine
    Vera, Carine
    Bonnemaire, Mireille
    Freemantle, Nick
    DIABETES OBESITY & METABOLISM, 2025, 27 (01): : 228 - 237
  • [35] EFFICACY AND SAFETY OF INSULIN GLARGINE-300 U/ML VS INSULIN DEGLUDEC-100 U/ML IN INSULIN-NAIVE ADULTS WITH T2DM: FIRST HEAD-TO-HEAD RANDOMISED CLINICAL TRIAL
    Cheng, A.
    Rosenstock, J.
    Ritzel, R.
    Bosnyak, Z.
    Devisme, C.
    Wang, X.
    Sieber, J.
    Roussel, R.
    Bolli, G. B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A30
  • [36] Type 2 Diabetes Treatment in Patients with Chronic Kidney Disease: Efficacy and Safety of Initiating Insulin Glargine 300 U/mL-REALI Pooled Data Analysis
    Mauricio, Didac
    Gourdy, Pierre
    Bonadonna, Riccardo C.
    Freemantle, Nick
    Bigot, Gregory
    Mauquoi, Celine
    Ciocca, Alice
    Bonnemaire, Mireille
    Mueller-Wieland, Dirk
    DIABETES, 2019, 68
  • [37] Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis
    Haluzik, Martin
    Seufert, Jochen
    Guja, Cristian
    Bonnemaire, Mireille
    Bigot, Gregory
    Tournay, Mathilde
    Kis, Janos Tibor
    Freemantle, Nick
    DIABETES THERAPY, 2023, 14 (04) : 639 - 652
  • [38] Methodologic Considerations for Data Source Selection and Study Design of Non-Interventional Studies Comparing the Safety and Effectiveness of Biosimilars and Reference Biologics: Insulin Glargine Products as a Case Example
    Lin, Nancy D.
    Bosco, Jaclyn L. F.
    Holmes, Cynthia H.
    Lockhart, Catherine M.
    Seeger, John D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 52 - 53
  • [39] Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis
    Martin Haluzík
    Jochen Seufert
    Cristian Guja
    Mireille Bonnemaire
    Gregory Bigot
    Mathilde Tournay
    János Tibor Kis
    Nick Freemantle
    Diabetes Therapy, 2023, 14 : 639 - 652
  • [40] INSTIGATE STUDY (INSULIN TITRATION; GAINING AN UNDERSTANDING OF THE BURDEN OF TYPE 2 DIABETES IN EUROPE): HEALTH CARE RESOURCE UTILIZATION AND COSTS WITHIN THE FIRST 6 MONTHS OF INSULIN THERAPY-FRENCH DATA
    Fagnani, F.
    Chartier, F.
    Salaun, Martin C.
    Tcherny-Lessenot, S.
    Pentel, J.
    Smith, T. H.
    Charles, M.
    VALUE IN HEALTH, 2008, 11 (06) : A505 - A505
12345